Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Randomized Controlled Trial and Economic Evaluation of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic (1-3 Metastases) Cancer (SABR-COMET-3)

NCT03862911 is registered in ClinicalTrials.gov with British Columbia Cancer Agency as lead sponsor.

NCT NCT03862911
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03862911 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Randomized Controlled Trial and Economic Evaluation of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic (1-3 Metastases) Cancer (SABR-COMET-3)
Lead sponsor
British Columbia Cancer Agency
Phase
Not applicable
Overall status
Active, not recruiting
Start date
November 1, 2019
Completion date
December 31, 2030
Enrollment
330 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic tumors